Orexo Adjusts Share Structure After U.S. Zubsolv Divestment

Orexo AB ( (SE:ORX) ) has provided an update.

Orexo AB’s board has approved the conversion of 416,417 Class C shares into ordinary shares and their transfer, free of charge, to former employees participating in the company’s long‑term incentive programs from 2023, 2024, and 2025. These participants, whose employment ended following the divestment of Orexo’s U.S. Zubsolv business to Dexcel Pharma USA, are being treated as “good leavers” under the incentive plan rules.

Following the conversion and share transfers, Orexo’s total share count will remain 37,156,639, but the composition will shift to 35,127,056 ordinary shares and 2,029,583 Class C shares. The company will hold no ordinary shares in treasury and will retain 2,029,583 Class C shares for ongoing incentive programs, clarifying its post‑divestment capital structure and aligning equity-based compensation with the reshaped organization.

The most recent analyst rating on (SE:ORX) stock is a Hold with a SEK27.00 price target. To see the full list of analyst forecasts on Orexo AB stock, see the SE:ORX Stock Forecast page.

More about Orexo AB

Orexo AB is a Swedish pharmaceutical company focused on treatments for severe diseases and life‑saving rescue medications. Its core innovation is the AmorphOX drug delivery technology, which enhances bioavailability and stability for small and large molecules, supporting new administration routes and more efficient manufacturing and distribution. With over 30 years of experience and several globally approved drugs, Orexo advances a diversified clinical and preclinical pipeline in partnership with research and commercialization collaborators.

Average Trading Volume: 74,406

Technical Sentiment Signal: Hold

Current Market Cap: SEK897.1M

Learn more about ORX stock on TipRanks’ Stock Analysis page.